https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41938 Wed 28 Feb 2024 14:51:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47147 post hoc cost-effectiveness analysis was undertaken. Part A: patient-level cost and health effect data (Multidimensional Fatigue Inventory (MFI) scores) were derived from the MIDAS trial and analysis undertaken from a health-system perspective. Part B: a secondary analysis simulated the societal impact of modafinil therapy in terms of national productivity costs. Results: Part A: Mean cost of modafinil treatment was AUD$3.60/day/patient for a minimally clinically important change (10 points) in total MFI fatigue score, i.e., AUD$0.36/day/unit change in fatigue score per patient. For the base case scenario, the ICER of using modafinil (versus placebo) was AUD$131.73 ($90.17 - 248.15, for minimum and maximum costs, respectively). Part B: The potential productivity cost-savings to society were calculated as nearly AUD$467 million over 1 year, and up to $383,471,991,248 over 10 years, from the widespread use of modafinil treatment in the Australian population of working-age stroke-survivors, representing a significant societal benefit. Conclusions: Modafinil is a highly cost-effective treatment for post-stroke fatigue, offering significant productivity gains and potential cost-savings to society from the widespread use of modafinil treatment in the Australian population of working-age stroke-survivors.]]> Wed 14 Dec 2022 15:27:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7153 Sat 24 Mar 2018 08:34:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5885 Sat 24 Mar 2018 07:49:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45724 Mon 07 Nov 2022 08:41:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40026 2=0%), US$3857.34 (95% CI US$−7293.93 to US$15 008.61, I²=45.9%), US$37 577.74 (95% CI US$−649.02 to US$75 804.50, I²=92.4%) and US$14 062.42 (95% CI US$8168.69 to US$19 956.15, I²=86.4%), respectively. GLP1s were statistically significantly cost-effective compared with insulins, but not compared with DPP4i, sulfonylureas, and TZDs. Among GLP1s, liraglutide was more cost-effective compared with lixisenatide, but not compared with exenatide, with corresponding pooled INBs of US$4555.09 (95% CI US$3992.60 to US$5117.59, I²=0) and US$728.46 (95% CI US$−1436.14 to US$2893.07, I²=0), respectively. Conclusion: GLP1 agonists are a cost-effective choice compared with insulins, but not compared with DPP4i, sulfonylureas and TZDs. PROSPERO registration number: CRD42018105193.]]> Fri 15 Jul 2022 10:11:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40089 p<0.0001), smoking (p<0.0001) and unknown stage (p = 0.002). There was no evidence of differences by year of diagnosis or sex (both p>0.50). For 465 cases diagnosed 2014–2015, 29% had subsidised molecular testing for targeted therapy/immunotherapy and 4% had subsidised targeted therapies. Conclusions: Lung cancer healthcare costs are strongly associated with survival-related factors. Costs appeared stable over the period 2006–2013. This study provides a framework for evaluating the health/economic impact of introducing lung cancer screening and other interventions in Australia.]]> Fri 15 Jul 2022 10:04:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45726 Fri 04 Nov 2022 09:52:02 AEDT ]]>